Balyasny Asset Management
NERV icon

Balyasny Asset Management’s Minerva Neurosciences NERV Stock Holding History

Balyasny Asset Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.7M Buy
+4,258,600
New +$24.4M 0.03% 590

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management's NERV Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Minerva Neurosciences (NERV) in Q1 2026: 4,258,600 shares worth $25.7M. The stake represents 0.03% of the portfolio and ranks #590 among its holdings.

47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

  • Balyasny Asset Management held 4,258,600 shares of Minerva Neurosciences worth $25.7M as of Q1 2026.
  • Minerva Neurosciences was a new Balyasny Asset Management position in Q1 2026.
  • Minerva Neurosciences made up 0.03% of Balyasny Asset Management's portfolio in Q1 2026, its #590 holding.
  • 47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.